Henry Gosebruch

Henry Gosebruch joined Galapagos as CEO and member of the Board of Directors on 12 May 2025, taking over from Paul Stoffels during the company's strategic refocus on small-molecule and biologics discovery. Before Galapagos, he served as President and CEO of Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on neuroscience. Earlier in his career he was Executive Vice President and Chief Strategy Officer at AbbVie, where he led corporate strategy, business development and M&A.